Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Small-Molecule GLP-1 Receptor Agonist in Obesity

The first annual report under an IND is often the first time a sponsor has to reconcile clinical, safety, nonclinical, and manufacturing information from several functions against one data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral, nonpeptide GLP-1 receptor agonist in adults with obesity. It accounts for a completed Phase 1 study (48 entered) and an ongoing Phase 2 study (92 of 150 planned entered), reports one IND safety report, an excipient supplier change, and a revision of the Investigator's Brochure, maps each element of 21 C.F.R. 312.33 to Module 1.13 of the eCTD, and sets out Form FDA 1571 entries, a draft cover letter, and a timeline to a January 30, 2027 deadline. It closes with the operational challenges that most often cause inconsistent or incomplete reports and how to prevent them.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24420527
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Small-Molecule GLP-1 Receptor Agonist in Obesity

Peivand Pirouzi, Riddhi Rohan Moradiya, Aditi Shivakumar Hipparagi
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Small-Molecule GLP-1 Receptor Agonist in Obesity

Peivand Pirouzi, Riddhi Rohan Moradiya, Aditi Shivakumar Hipparagi
article en

Abstract

The first annual report under an IND is often the first time a sponsor has to reconcile clinical, safety, nonclinical, and manufacturing information from several functions against one data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral, nonpeptide GLP-1 receptor agonist in adults with obesity. It accounts for a completed Phase 1 study (48 entered) and an ongoing Phase 2 study (92 of 150 planned entered), reports one IND safety report, an excipient supplier change, and a revision of the Investigator's Brochure, maps each element of 21 C.F.R. 312.33 to Module 1.13 of the eCTD, and sets out Form FDA 1571 entries, a draft cover letter, and a timeline to a January 30, 2027 deadline. It closes with the operational challenges that most often cause inconsistent or incomplete reports and how to prevent them.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon